Table 1 |.

Ongoing phase III studies of adjuvant therapy in non-metastatic non-small cell lung cancer.

Drug	Comparator group	n	Biomarker tested	Biomarker selected	Chemotherapy	End point	Refs
Crizotinib	Observation	168	ALK fusion	Yes	SOC	OS	NCT02201992 (REF.132)
Erlotinib	Observation	450	EGFR mutation	Yes	SOC	OS	NCT02193282 (REF.133)
Osimertinib	Placebo	688	EGFR mutation	Yes	SOC	DFS	NCT02511106 (REF.62)
Nivolumab	Observation	905	PD-L1 positivity	No	SOC	DFS and OS in all patients DFS in patients with high PD-L1 (≥50% staining)	NCT02595944 (REF.134)
Pembrolizumab	Placebo	1,177	PD-L1 positivity	No	SOC	DFS	NCT02504372 (REF.135)
Atezolizumab	Observation	1,280	PD-L1 positivity	No	Cisplatin doublet	DFS in all patients (including PD-L1 subgroup)a	NCT02486718 (REF.136)
Durvalumab	Placebo	1,360	PD-L1 positivity	No	SOC	DFS in patients with PD-L1 ≥25% in tumour cells	NCT02273375 (REF.137)
Durvalumab	Placebo	332	ctDNA	Yes	Platinum doublet	DFS	NCT04385368 (REF.129)
Canakinumab	Placebo	1,500	None	No	SOC	DFS	NCT03447769 (REF.138)

^aFurther details not provided.

ctDNA, circulating tumour DNA; DFS, disease-free survival; OS, overall survival; PD-L1, programmed death ligand 1; SOC, standard of care.